Drugs & Therapy Perspectives

, Volume 18, Issue 6, pp 8–11

A multi-pronged approach required for management of complications of cirrhosis of the liver

Disease Management
  • 16 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anand BS. Drug treatment of the complications of cirrhosis in the older adult. Drugs & Aging 2001; 18(8): 575–85CrossRefGoogle Scholar
  2. 2.
    Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264–72PubMedCrossRefGoogle Scholar
  3. 3.
    Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–7PubMedCrossRefGoogle Scholar
  4. 4.
    Lake JR. The role of transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1745–7PubMedCrossRefGoogle Scholar
  5. 5.
    Runyon BA, McHutchinson JG, Antillon MR, et al. Short-course versus long course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 1737–42PubMedGoogle Scholar
  6. 6.
    Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–9PubMedCrossRefGoogle Scholar
  7. 7.
    Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716–24PubMedCrossRefGoogle Scholar
  8. 8.
    Bernard B, Grange JD, Nguyen Khac E, et al. Antibiotic prophylaxis for prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998; 59 Suppl. 2: 54–7PubMedCrossRefGoogle Scholar
  9. 9.
    Westaby D, Hayes P, Gimson AE, et al. Controlled trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989; 9: 274–7PubMedCrossRefGoogle Scholar
  10. 10.
    D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–54PubMedGoogle Scholar
  11. 11.
    Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988–93PubMedCrossRefGoogle Scholar
  12. 12.
    Conn HO. Animal versus vegetable protein diet in hepatic encephalopathy. J Intern Med 1993; 233: 369–71PubMedCrossRefGoogle Scholar
  13. 13.
    Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1691–7CrossRefGoogle Scholar
  14. 14.
    Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870–5PubMedCrossRefGoogle Scholar
  15. 15.
    Guevara M, Gines P, Bandi JC, et al. Transjugular portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations